This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...